The UK and US have announced a significant trade agreement that will preserve no levies on British medicine shipments entering the US market.
The Terms of the Pact
As part of the deal, the UK has agreed to raise funding on pharmaceuticals through the NHS. This pledge secures that import taxes on these key goods will remain at zero for a period of the next three years.
This agreement follows recent warnings to significantly raise tariffs on branded pharmaceutical products, with increases mentioned as high as 100%.
"This arrangement with the Britain strengthens the international landscape for innovative medicines and brings much-needed fairness to transatlantic medicine commerce," a release noted.
Trade Importance
Medicines are one of the UK's largest goods shipped to the US, which is easily the primary market for major UK drugmakers.
Export figures reveal that in the 12 months leading up to the third quarter, the UK shipped medicines valued at over eleven billion pounds to the US. This value represented a significant portion of British export trade in that timeframe.
"This deal safeguards jobs, stimulates capital expenditure and facilitates the UK to establish itself as a worldwide center for medical research," a minister commented.
Specific UK Commitments
The agreement includes several specific commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to increase overall public funding on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must pay back to the NHS to prevent overspending will be limited at fifteen percent. In the past, refunds topped 20%.
Recent Tensions
This agreement follows a ongoing tension between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
This friction were heightened by claims that US customers were paying significantly more for the identical medicines than people in the Britain and the EU.
In recent months, several large drug company projects in the UK have been delayed or abandoned, while substantial investments have been directed toward US facilities.
The Science Minister acknowledged that the NHS must invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a percentage of its resources over the previous ten-year period.
